IMU Biosciences
Biotechnology company that develops high-resolution, multi-omic immune profiling and AI/ML analytics to generate population-scale immune datasets and clinically actionable immune signatures for diagnostics, drug development, and precision medicine. Works with academic, pharma and biotech partners to deliver biomarker discovery, patient stratification and immune monitoring services.
Industries
Nr. of Employees
small (1-50)
IMU Biosciences
IMU Biosciences, 20 Water Street, Wood Wharf, London E14 5GX, UK
Products
Proprietary immune profiling and analytics platform
Integrated multi-omic platform that produces high-resolution immune profiles, applies AI/ML analytics, and compares individual profiles to a large population reference dataset to generate clinically actionable signatures.
Proprietary immune profiling and analytics platform
Integrated multi-omic platform that produces high-resolution immune profiles, applies AI/ML analytics, and compares individual profiles to a large population reference dataset to generate clinically actionable signatures.
Services
End-to-end immune phenotyping and AI/ML analysis services for research partners and industry to generate systems-level immune signatures from blood samples.
Identification and development of immune biomarkers and predictive models to support diagnostics, companion diagnostics and monitoring in clinical studies.
End-to-end immune phenotyping and AI/ML analysis services for research partners and industry to generate systems-level immune signatures from blood samples.
Identification and development of immune biomarkers and predictive models to support diagnostics, companion diagnostics and monitoring in clinical studies.
Expertise Areas
- Systems-level immune profiling
- Biomarker discovery and validation
- Immuno-oncology translational research
- Cell therapy and transplantation immune analytics
Key Technologies
- Single-cell proteomics
- Single-cell transcriptomics
- High-dimensional cytometry
- Multi-omic data integration
News & Updates
Series A financing to advance the company's platform and expand operations; describes platform application across diagnostics, drug development, and cell therapy.
Announcement of inclusion in NVIDIA Inception to access GPU/HPC resources and AI expertise to accelerate ML-driven precision medicine development.
Participation in a multi-institution UK consortium to analyse thousands of blood samples and develop predictive biomarkers for immunotherapy response and toxicity.
Formation of a Scientific Advisory Board composed of leading experts in haematology, vaccinology, immunology and genetics to advise on scientific strategy.
Board appointment highlighting experience in drug development and commercial strategy to support platform application across diagnostics and drug development.
Closed £11.5M Series A to expand platform development, partnerships and operations.
Series A financing to advance the company's platform and expand operations; describes platform application across diagnostics, drug development, and cell therapy.
Announcement of inclusion in NVIDIA Inception to access GPU/HPC resources and AI expertise to accelerate ML-driven precision medicine development.
Participation in a multi-institution UK consortium to analyse thousands of blood samples and develop predictive biomarkers for immunotherapy response and toxicity.
Formation of a Scientific Advisory Board composed of leading experts in haematology, vaccinology, immunology and genetics to advise on scientific strategy.
Board appointment highlighting experience in drug development and commercial strategy to support platform application across diagnostics and drug development.
Closed £11.5M Series A to expand platform development, partnerships and operations.